Nexalin announces results for 15 mA neurostimulation device

Nexalin Technology (NXL) announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-intensity transcranial alternating current stimulation for gambling disorder comorbidities with alcohol use disorders: A case report.” The study evaluated the safety and efficacy of Nexalin’s 15 milliamp, mA, neurostimulation device in a patient diagnosed with both gambling disorder and alcohol use disorder. Following 20 outpatient treatment sessions over 10 days, the patient achieved complete abstinence from gambling and alcohol, along with marked improvement in cognitive control and no adverse effects during a three-month follow-up period.